Introduction {#sec1}
============

Scorpion envenomation affects more than 1 million subjects every year ([@ref5]; [@ref7]). In Brazil, stings by the scorpion *Tityus serrulatus* contribute significantly for this scenario, whose venom (TsV) is composed by a cocktail of bioactive compounds ([@ref14]). In recent years, it became clear that beyond the classical neuroexcitatory syndrome, inflammation also underlies the pathology and mortality caused by TsV. We and others have demonstrated that crude TsV or isolated toxins (Ts1, Ts2, Ts6) induce the production of inflammatory mediators by innate immune cells, including cytokines, nitric oxide (NO), and bioactive lipids such as prostaglandin E~2~ (PGE~2~) and leukotriene B~4~ (LTB~4~) ([@ref11]; [@ref13]; [@ref12]; [@ref18], [@ref19]). Macrophages sense TsV *via* TLR2, TLR4, or CD14, which control the release of PGE~2~ and interleukin-1β (IL-1β) ([@ref17], [@ref23], [@ref21]). PGE~2~ signals through EP2/4 receptors, increasing intracellular levels of cyclic adenosine monophosphate (cAMP). The cAMP-dependent protein kinase A (PKA) is activated and phosphorylates the nuclear factor-κB (NF-κB), potentiating IL-1β release ([@ref23]). IL-1R signaling mediates activation and accumulation of neutrophils in the lung, edema, and eventually death in a mouse model of scorpion envenomation ([@ref23]). In stark contrast to other receptors, CD36 promotes intracellular signaling that favors LTB~4~ release ([@ref21]). This eicosanoid reduces intracellular cAMP *via* BLT1 receptor and suppresses IL-1β production and mortality due to scorpion envenomation ([@ref23], [@ref21]). Of importance, molecular mechanisms governing responses to TsV in mouse models are strongly correlated with that of human cell responses ([@ref21]).

Recommended therapy is limited to antivenom serum, and depending on the severity, the serum is combined with supportive treatment such as prazosin, ionotropic agents, atropine, vasodilators, and benzodiazepines ([@ref2]; [@ref7]). However, current therapeutic strategies do not account for tissue damage and mortality caused by TsV-induced inflammation ([@ref23]). EP80317 is a synthetic analog of growth hormone-releasing peptides, which serves as a ligand for CD36 and exhibits cardioprotective, anti-atherosclerotic, hypocholesterolemic, and anticonvulsant effects ([@ref9]; [@ref4], [@ref3]; [@ref6]; [@ref1]; [@ref8]). EP80317 activates the peroxisome proliferator-activated receptor gamma (PPAR-γ) ([@ref4]), a nuclear receptor that regulates lipid bodies and lipid metabolism in response to TsV ([@ref22]). In line with these findings, we investigated whether EP80317 limits TsV-mediated inflammation and mortality in a mouse model.

Materials and Methods {#sec2}
=====================

*Tityus serrulatus* Venom (TsV) {#sec3}
-------------------------------

In accordance with the Brazilian Institute of Environment, *T. serrulatus* scorpions were maintained at the vivarium of the Ribeirão Preto Medical School, University of São Paulo. TsV was obtained by electrical stimulation, lyophilized, weighted, and stored at −80°C. Before experiments, TsV was diluted in PBS, filtered, and tested for LPS contamination as described ([@ref17], [@ref21]).

Mice and Experimental Settings *in vivo* {#sec4}
----------------------------------------

All experiments using animals were approved by the Comissão de Ética no Uso de Animais da Faculdade de Ciências Farmacêuticas de Ribeirão Preto-USP (protocol \#14.1.272.53.7). Six- to eight-week-old C57BL/6 female or male mice were weighed before experiments under all conditions. Animals were injected with vehicle (PBS) or a lethal (180 μg/kg, i.p.) or excessive (super dose; 360 μg/kg, i.p.) dose of TsV ([@ref23]). Following this, TsV-injected animals were treated with vehicle or EP80317 (0.289 μmol/kg, i.p.) at 0.5 and 2 h after the venom injection ([@ref9]; [@ref1]; [@ref3]). Mice were followed during 8 h and sacrificed upon signs of severe envenomation such as difficult of breathing, unusual head, neck and eye movement, and sweating. Euthanasia was performed with an overdose of chemical anesthetics (100 mg/kg ketamine and 10 mg/kg xylazine). In one set of animals, bronchoalveolar lavage fluid (BALF) was collected for total leukocyte and neutrophil counts. In another set of animals, lungs were removed, weighted, homogenized, and stored at −80°C.

Isolation and Treatment of Murine Peritoneal Macrophages {#sec5}
--------------------------------------------------------

Resident peritoneal macrophages (PMs) were isolated from naïve C57BL/6 mice by injecting 3 ml of PBS into the abdominal cavity and massaged for 1 min. Peritoneal fluid then collected using a syringe with a needle inserted into the inguinal region as described previously ([@ref19]). PMs (2 × 10^5^ cells/well) were cultured at 37°C, 5% CO~2~ for 2 h. After this period, PMs were incubated with EP80317 (100 nM) or vehicle (PBS) for 2 h, followed by stimulation with TsV (50 μg/ml) for 24 h at 37°C, 5% CO~2~. Culture supernatants were collected and stored at −20°C for further analysis.

Quantification of Soluble Mediators and NF-κB Phosphorylation {#sec6}
-------------------------------------------------------------

Cell culture supernatants and lung homogenates were used to quantify IL-1β, IL-6, TNF-α, CCL3 (MIP-1α), and IL-10 using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, United States). Quantifications of LTB~4~ and PGE~2~ were performed by enzymatic immunoassays (Enzo Life Sciences, NY, United States), after lipid extraction and purification from cell culture supernatants or lung homogenates using Sep-Pak C18 cartridges (Thermo Fisher Scientific, Bellefonte, PA, United States), as described previously ([@ref21]). Total protein was quantified using Coomassie Protein Assay Reagent (Pierce Chemical, Rockford, IL, United States). Nitrite (NO~2~ ^−^) was measured as an indicator of NO production by obtaining a standard curve using serial NaNO~2~ dilutions, as described ([@ref18]). cAMP was quantified by ELISA, according to the manufacturer's instructions (Enzo Life Sciences, Farmingdale, NY, United States), as described ([@ref21]). Cell cultures were lysed to measure phospho-NF-κB p65 (Ser536) and total NF-κB p65 using the PathScan Inflammation Multi-Target Sandwich ELISA kit (Cell Signaling, Danvers, MA, United States) as described ([@ref20]).

Statistical Analyses {#sec7}
--------------------

Data were analyzed with GraphPad Prism 5.0 software (GraphPad, San Diego, CA, United States), using one-way ANOVA followed by Bonferroni's multi-comparison test or log-rank test. Adjusted *p* values \<0.05 were considered significant.

Results {#sec8}
=======

EP80317 Suppresses TsV-Induced Inflammation and Mortality *in vivo* {#sec9}
-------------------------------------------------------------------

EP80317 mediates protective effects *via* CD36 ([@ref9]; [@ref4], [@ref3]; [@ref6]; [@ref1]; [@ref8]), a scavenger receptor that drives eicosanoid metabolism toward LTB~4~ synthesis and represses inflammation and mortality caused by scorpion envenomation ([@ref23], [@ref21]). This suggests that binding of EP80317 to CD36 could modulate LTB~4~ metabolism and influence the outcome of scorpion envenomation. To test this hypothesis, C57BL/6 mice were injected with a lethal dose of TsV (180 μg/kg, i.p.) and treated with vehicle or EP80317 (0.289 μmol/kg, i.p.) at 0.5 and 2 h after the experimental envenomation. TsV injection in mice causes significant perturbations in the lung ([@ref23], [@ref21]), prompting for detailed analysis of inflammatory parameters in this organ. As expected, TsV induced an intense inflammatory response reflected by elevated lung weight ([Figure 1A](#fig1){ref-type="fig"}), total protein content ([Figure 1B](#fig1){ref-type="fig"}), accumulation of total leukocytes ([Figure 1C](#fig1){ref-type="fig"}), and neutrophils ([Figure 1D](#fig1){ref-type="fig"}), as by increased levels of IL-1β ([Figure 1E](#fig1){ref-type="fig"}), NO ([Figure 1F](#fig1){ref-type="fig"}), PGE~2~ ([Figure 1G](#fig1){ref-type="fig"}), and LTB~4~ ([Figure 1H](#fig1){ref-type="fig"}). Strikingly, treatment with EP80317 significantly impacted the inflammatory response, promoting further increase of LTB~4~ levels ([Figure 1H](#fig1){ref-type="fig"}) while reducing all other parameters ([Figures 1A](#fig1){ref-type="fig"}--[G](#fig1){ref-type="fig"}). These results suggest that EP80317 might restrain the inflammation-mediated mortality induced by TsV. To address this question, C57BL/6 mice were injected with a lethal (180 μg/kg, i.p.) or an excessive (super dose; 360 μg/kg, i.p.) dose of TsV and later treated with vehicle or EP80317 (0.289 μmol/kg, i.p.) at 0.5 and 2 h after the experimental envenomation. We observed 75% mortality of mice injected with a lethal dose of TsV, whereas 100% of mice survived after treatment with EP80317 ([Figure 1I](#fig1){ref-type="fig"}). Moreover, excessive TsV dose induced 100% of mortality, independently of EP80317 treatment ([Figure 1J](#fig1){ref-type="fig"}). However, non-treated mice died within 4 h of envenomation, while EP80317 significantly extended mice survival.

![Treatment with EP80317 protects mice from scorpion envenomation. **(A--H)** C57BL/6 mice were injected with a lethal dose of TsV (180 μg/kg, i.p.) and treated with vehicle (PBS) or EP80317 (0.289 μmol/kg, i.p.) at 0.5 and 2 h after the venom injection. Lungs were removed immediately after death or at 8 h after venom injection. BALF was collected from a different set of animals under the same condition. **(A)** Lung weight, **(B)** Lung total protein concentration, (**C**) BALF total leukocyte counts, **(D)** BALF neutrophil counts**, (E)** IL-1β levels, **(F)** NO levels, **(G)** PGE~2~ levels, and **(H)** LTB~4~ levels. The experiment was conducted once with six mice per group. Differences were evaluated with one-way ANOVA followed by Bonferroni's multi-comparison test. **(I,J)** C57BL/6 mice were injected with a **(I)** lethal (180 μg/kg, i.p.) or **(J)** excessive (superdose; 360 μg/kg, i.p.) dose of TsV and treated with vehicle (PBS) or EP80317 (0.289 μmol/kg, i.p.) 0.5 and 2 h after the venom injection. Survival was monitored for 8 h. The experiment was performed once with six mice per group, and the log-rank test was used to analyze significant differences. Data represent mean ± SDs, and significance is given by \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001.](fphar-10-00171-g001){#fig1}

EP80317 Modulates Inflammatory Pathways in Macrophages Activated by TsV {#sec10}
-----------------------------------------------------------------------

To determine the molecular mechanisms by which EP80317 restrains inflammation and mortality induced by TsV, peritoneal macrophages were isolated from C57BL/6 mice and incubated or not with EP80317 for 2 h. Following, macrophages were stimulated with TsV for 24 h in the presence of EP80317 throughout the challenge. Macrophages stimulated with TsV produced increased levels of the pro-inflammatory cytokines IL-1β ([Figure 2A](#fig2){ref-type="fig"}), IL-6 ([Figure 2B](#fig2){ref-type="fig"}), and TNF-α ([Figure 2C](#fig2){ref-type="fig"}); the chemokine CCL3 ([Figure 2D](#fig2){ref-type="fig"}); the second messenger cAMP ([Figure 2E](#fig2){ref-type="fig"}); and the bioactive lipids PGE~2~ ([Figure 2F](#fig2){ref-type="fig"}) and LTB~4~ ([Figure 2G](#fig2){ref-type="fig"}). Of note, exposure to EP80317 potentiated LTB~4~ synthesis ([Figure 2G](#fig2){ref-type="fig"}) and induced the production of the anti-inflammatory cytokine IL-10 ([Figure 2H](#fig2){ref-type="fig"}). At the same time, EP80317 abrogated the production of IL-1β ([Figure 2A](#fig2){ref-type="fig"}), IL-6 ([Figure 2B](#fig2){ref-type="fig"}), and cAMP ([Figure 2E](#fig2){ref-type="fig"}) and significantly reduced levels of TNF-α ([Figure 2C](#fig2){ref-type="fig"}), CCL3 ([Figure 2D](#fig2){ref-type="fig"}), and PGE~2~ ([Figure 2F](#fig2){ref-type="fig"}). The transcription factor NF-κB targets genes coding for these cytokines, chemokine, or even the rate-limiting enzyme involved in PGE~2~ synthesis, cyclooxygenase-2 (COX-2). This suggests that EP80317 might restrain the production of inflammatory mediators by suppressing NF-κB activity. As expected, exposure to EP80317 significantly reduced NF-κB phosphorylation induced by TsV stimulation ([Figure 2I](#fig2){ref-type="fig"}).

![EP80317 inhibits NF-κB activation and production of inflammatory mediators in TsV-stimulated macrophages. **(A--H)** Peritoneal macrophages (PMs) were incubated or not with EP80317 (100 nM) for 2 h and later stimulated with TsV (50 μg/ml) for 24 h for quantification of cytokines/chemokine, or 5 min. for quantification of cAMP. **(A)** IL-1β, **(B)** IL-6, **(C)** TNF-α, **(D)** CCL3, **(E)** cAMP, **(F)** PGE~2~, **(G)** LTB~4~, and **(H)** IL-10. **(I)** PMs were pre-treated or not with EP80317 (100 nM) for 2 h and then stimulated with TsV (50 μg/ml). Cell lysates were obtained 2 h later for phospho-NF-κB p65 (Ser536) and total NF-κB p65 quantification. Data represent one of two independent experiments (*n* = 4 replicates). Differences were evaluated with one-way ANOVA followed by Bonferroni's multi-comparison test. Data represent mean ± SDs, and significance is given by \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001.](fphar-10-00171-g002){#fig2}

Discussion {#sec11}
==========

Here, we explored the therapeutic potential of the CD36 ligand, EP80317, for the control of inflammation-dependent mortality caused by scorpion envenomation. Overall, data point to a model of action in which EP80317 interacts with CD36 and dampens TsV-mediated inflammation *via* molecular mechanisms that are at least partially dependent on LTB~4~ production *in vitro* and *in vivo*. Signaling *via* BLT1 receptor inhibits cAMP synthesis and reduces the activation of PKA, consequently diminishing NF-κB phosphorylation and activation ([@ref23]). This results in reduced levels of diverse inflammatory mediators, including IL-1β. EP80317 induces intracellular increase of 15-deoxy-delta(12,14)-prostaglandin J~2~ (15d-PGJ~2~) *via* COX-2 pathway in macrophages ([@ref4]). PPAR-γ negatively regulates NF-κB in macrophages stimulated with TsV ([@ref22]), while 15d-PGJ~2~ activates this transcription factor and might contribute to reduced inflammation. PGE~2~ and the precursor of 15d-PGJ~2~, PGD~2~, exhibit opposite effects on macrophages ([@ref10]). Thus, PGD~2~ could also play a significant role in this process by downregulating cAMP levels *via* DP2 receptor and influence NF-κB activity. Taken together, these data provide important insights into operating molecular mechanisms and potential supportive therapy with EP80317. It also encourages further investigation during envenomation by other scorpions or even other poisonous animals, since similar molecular mechanisms take place upon stimulation of cells with venoms from two species of *Bothrops* snakes ([@ref20]).

Interestingly, CD36 activates the p130Cas-binding kinase Pyk2 in macrophages stimulated with oxidized phospholipid, whereas previous exposure to EP80317 inhibits Pyk2 phosphorylation ([@ref6]). This correlated with reduced levels of plasma IL-6, as well as reduced expression of NADPH oxidase, inducible nitric oxide synthase and CCL2 in the vasculature of apolipoprotein E-deficient mice fed a high-fat, high-cholesterol diet, and treated daily with EP80317 ([@ref6]). Although we have observed that EP80317 promotes LTB~4~ synthesis or that CD36 deficiency abrogates the production of this lipid mediator in response to TsV ([@ref21]), the signaling pathways leading to this phenomenon are unknown. Furthermore, we observed previously that CD36 deficiency increases IL-1β release by macrophages stimulated with TsV, but cytokines such as IL-6 and TNF-α were significantly reduced ([@ref21]). With exception of LTB~4~ and IL-10, treatment with EP80317 significantly reduced all the evaluated inflammatory parameters, suggesting additional anti-inflammatory mechanisms. Indeed, EP80317 could induce TLR heterodimer complex dissociation and suppress TLR-mediated signaling ([@ref16]; [@ref15]). However, TLR2 deficiency enhances PGE~2~ production by macrophages upon TsV stimulation ([@ref21]). Beneficial inhibition of the immune response during scorpion envenomation is further supported by the fact that dexamethasone, a potent immunosuppressive compound, completely abrogates IL-1β release by human peripheral blood mononuclear cells in response to TsV ([@ref21]). Collectively, these studies provide a proof of concept for the therapeutic potential of EP80317 during scorpion envenomation, involving multiple signaling pathways in mitigating inflammation induced by TsV.
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